Substance | Author(s) | Year | Study type | N | tumour | RT dose/ChTx/technique | Toxicity |
---|---|---|---|---|---|---|---|
Sunitinib | Chi et al. [153] | 2010 | Phase II | 23 | HCC | 52.5 (15 Fx) IMRT/3D-CT | 9% grade III upper GI bleeding, 4% hepatitis grade III/4% grade III pancreatitis, 26% grade III + IV thrombopenia, 4% grade III leukopenia |
 | Stähler et al. [154] | 2010 | Prospective, non-randomized | 22 | RCC (all sites) | Median 40 Gy (median 8 Fx) | 5% grade IV hypertension, 14% grade III + IV nausea |
 | Kao et al. [80] | 2009 | Phase I | 21 | Oligometastases | 40-50 Gy (10 Fx) | 62% grade III + IV lymphopenia, 19% grade III neutropenia, 14% grade III + IV thrombopenia, 5% grade III rectal bleeding |
 | Hui et al. [155] | 2010 | Phase II | 13 | Nasopharyngeal carcinoma | Sunitinib after RT (60-70 Gy) and multiple Chx | 15% fatal hemorrhages, 31% Grade IV hemorrhages, (among other toxicities) |
sorafenib | Peters et al. [77] | 2008 | Case study | 1 | RCC | 8 Gy single dose | Grade V bowel perforation (stopped two days before, three days later recommenced) |
lapatinib | Harrington et al. [156] | 2009 | Phase I | 31 | LA-HNSCC | 66-70 Gy + CisPt | 35% grade III mucositis, 19% grade III dermatitis, 13% grade III + IV lymphopenia, 6% grade III neutropenia |
gefitinib | Cohen et al. [157] | 2010 | Phase I | 69 | LA-HNSCC | IC Carbo/Tax, hydroxyurea + 5-FU, 2 × 1.5 Gy/d | 29% grade III + IV neutropenia, 86% grade III + IV mucositis, 33% grade III + IV dermatitis, 3% grade V infections, 17% grade III + IV infections, 4% grade III rash, 3% grade III neurotoxicity |
 | Pollack et al. [158] | 2011 | Phase II | 43 | Brainstem glioma in children | 55,8 Gy | Grade III+IV: lymphopenia (21%), neutropenia (2%), GI (12%), infection (7%), n, pulmonary (5%), renal, skin (2%), metabolic (2%), intratumoral hemorrhage: 7%. |
 | Valentini et al. [159] | 2008 | Phase I/II | 41 | Rectal cancer | 45 Gy + 5.4 Gy + 5-FU | 20% grade III + IV GI toxicity, 15% grade III + IV skin toxicity, 39% grade III + IV hepatic toxicity, 10% grade III + IV GU toxicity, 7% other toxicities grade III + IV |
 | Wang et al. [160] | 2011 | Prospective | 26 | Stage III/IV NSCLC | Median 70 Gy | Grade IV leukopenia 4%, grade IV thrombopenia 8%, grade III esophagitis 4%, grade III pneumonitis 4% |
 | Zhang et al. [161] | 2009 | Phase I | 24 | NSCLC | 54-60 Gy | 4% grade III nausea |
 | Chen et al. [162] | 2007 | Phase I | 23 | HNSCC | Up to 72 Gy | 13% grade III dermatitis, 57% grade III + IV mucositis, 39% grade III + IV dysphagia, 17% grade III + IV diarrhea, 30% grade III + IV neutropenia, 9% grade III + IV anemia, 4% grade IV tumour hemorrhage, 4% grade III GI bleeding |
 | Maurel et al. [163] | 2006 | Phase I | 18 | Pancreatic cancer | 45 Gy | No DLT, 11% grade III + IV neutropenia, 6% anemia grade III |
 | Czito et al. [164] | 2006 | Phase I | 16 | Pancreatic + rectal cancer | 50.4 Gy (1.8 Gy) + capecitabine | 31% grade III + IV diarrhea |
 | Center et al. [165] | 2010 | Phase I | 16 | NSCLC | 70 Gy 3D-CT + docetaxel | 27% grade III + IV hematotoxicity, 27% grade III + IV esophagitis, 20% grade III + IV pulmonary toxicity |
 | Schwer et al. [166] | 2008 | Phase I | 15 | Malignant glioma | SRS 18-36 Gy | No DLT, no grade > II |
 | Olsen et al. [167] | 2009 | Phase I | 12 | Pancreatic cancer | 50.4 Gy (1.8 Gy) | 45% grade III nausea |
erlotinib | Brown et al. [168] | 2008 | Phase I/II | 79 | GBM | 60 Gy + TMZ | 18% grade III/IV rash, 16% grade III/IV fatigue, 24% grade III/IV thrombopenia, 4% grade III nausea, 8% grade III diarrhea, 28% grade III/IV leukopenia, 3% grade III anorexia, 18% grade III/IV neutropenia, 6% grade III anemia, 14% grade III lymphopenia, 1% grade V infection without neutropenia, 5% grade III infection without neutropenia, 6% grade III/IV dyspnea, 1% grade III/IV keratitis, 1% grade V pneumonitis, 6% grade III/IV pneumonitis |
 | Prados et al. [169] | 2009 | Phase II | 65 | GBM | 59.4 Gy/60 Gy + TMZ | 43% grade III lymphopenia, 3% grade IV neutropenia, 2% grade IV thrombopenia, 8% grade III/IV fatigue, 2% grade III diarrhea, 6% grade III rash |
 | Herchenhorn et al. [170] | 2010 | Phase I/II | 37 | LA-HNSCC | 70 Gy + Cis | No DLT |
 | Choong et al. [171] | 2008 | Phase I | 34 | NSCLC Stage III | 66 Gy (2 Gy), Arm A: Erlotinib + Cis/Eto, Arm B: Induction Carbo/Tax, Carbo/Tax + Erlotinib | 41% grade III + IV WBC, 32% grade III + IV neutropenia, 21% grade III + IV thrombopenia, 26% grade III + IV esophagitis, 3% grade III + IV vomiting, 6% grade III + IV diarrhea, 3% grade III/IV pneumonitis/ototoxicity |
 | Peereboom et al. [172] | 2010 | Phase II | 27 | GBM | 60 Gy + TMZ | 7% grade V febrile neutropenia, 4% grade V sepsis without neutropenia, 4% grade V PCP, a pt grade III neutropenia, 15% grade III neutropenia, 30% grade III + IV thrombopenia, 56% pts grade III lymphopenia, 15% grade III + IV anemia, 7% grade III fatigue |
 | Chang et al. [173] | 2011 | Retrospective | 25 | NSCLC | 40-50 Gy | 4% grade III rash, 4% grade III diarrhea/esophagitis/anemia, 8% grade III neutropenia/thrombopenia, 8% grade V pneumonitis, 4% grade III pneumonitis |
 | Li et al. [174] | 2010 | Phase II | 24 | LA esophageal cancer | 60 Gy + Carbo/Tax | 17% ≥ grade III leukopenia, 8% thrombopenia ≥ grade III |
 | Broniscer et al. [175] | 2009 | Phase I | 23 | GBM | 54-59.4 Gy | 39% grade III + IV lymphopenia, 4% grade III rash, 4% grade III diarrhea |
 | Robertson et al. [176] | 2009 | Phase I | 22 | Pancreatic cancer | Gem weekly, 30-38 Gy | 5% grade III vomiting/fatigue/nausea, 5% grade III vomiting/diarrhea/nausea, 9% grade IV fatigue |
 | Duffy et al. [177] | 2008 | Phase I | 20 | Pancreatic cancer | 50.4 Gy + Gem | 100% grade III lymphopenia, 25% grade III thrombopenia, 30% grade III neutropenia, 5% grade IV neutropenia, 10% grade III anemia, 5% grade III fatigue, 15% grade III diarrhea, 10% grade III rash |
 | Krishnan et al. [178] | 2006 | Phase I | 20 | GBM | 60 Gy | 15% grade III stomatitis, 5% grade III fatigue/diarrhea |
 | Iannitti et al. [179] | 2005 | Phase I | 17 | LA Pancreatic cancer | 50.4 Gy + Tax/Gem | 6% grade III nausea/fatigue/rash/small bowel stricture/thrombopenia (each), 18% grade III dehydration/thrombosis, 12% grade III diarrhea/hypersensitivity, 6% grade IV neutropenia |
 | Nogueira-Rodrigues et al. [180] | 2008 | Phase I | 15 | LA cervical cancer | 45 Gy + brachyTx + CisPt | 7% grade IV hepatotoxicity, 7% grade III dermatitis, 20% III diarrhea, 13% grade III rash |
 | Arias de la Vega et al. [181] | 2011 | Phase I | 13 | LA-HNSCC | 63 Gy + Cis adjuvant | Grade III/IV: Mucositis 54%, Asthenia 15%, skin 23%, diarrhea 15%. |
 | Lind et al. [182] | 2009 | Phase I | 11 | NSCLC, brain metastases | WBRT (30 Gy) | 9% grade III rash/fatigue |
 | Dobelbower et al. [183] | 2006 | Phase I | 11 | Esophageal cancer | 50.4 Gy + 5-FU | 36% pts grade III + IV leukopenia, 9% grade III anemia, 9% grade III thrombopenia, 18% grade III + IV neutropenia, 27% grade III dehydration, 9% grade III nausea, 9% grade III/9% grade IV esophagitis |
 | Silvano et al. [82] | 2008 | Case report | 1 | NSCLC | 2 × 8 Gy | Death caused by fatal diarrhea |
 | Huang et al. [184] | 2008 | Case study | 1 | NSCLC | WBRT 37.5 Gy | Death caused by exacerbated radiodermatitis and subdural hemorrhage |
mTOR inhibitors (Sirolimus) | Sarkaria et al. [185] | 2007 | Phase I | 7 | NSCLC | 60 Gy + CisPt weekly | 14% grade III dysphagia, esophagitis, febrile neutropenia, pneumonia |
 | Bourgier et al. [186] | 2011 | Case reports | 3 | Breast/prostate/ovary cancer | 45 Gy/70 Gy, later | Gastrointestinal radiation recall syndrome with everolimus/temsirolimus |